2 Beaten-Down Stocks to Avoid Right Now

Intellia Therapeutics and Sarepta Therapeutics are facing significant clinical and commercial headwinds, making their recent stock dips unattractive for investors. Intellia's lead gene-editing candidate, nexiguran ziclumeran, had its clinical trials paused following a patient death from liver damage, highlighting the inherent risks in the gene-editing space. Similarly, Sarepta's Duchenne muscular dystrophy gene therapy, Elevidys, was linked to two patient deaths from acute liver failure, with a third death occurring in another investigational therapy, leading to a 15% year-over-year Q3 revenue decline to $399.4 million and a non-GAAP net loss of $0.13 per share. These critical safety concerns are expected to result in regulatory restrictions, including potential label changes and warnings, significantly elevating the risk profiles and limiting the sales potential for both companies.

Analysis

Intellia Therapeutics (NTLA) and Sarepta Therapeutics (SRPT) are confronting severe clinical and regulatory challenges stemming from patient deaths linked to liver damage across their gene-editing therapies, contributing to a "strongly negative" sentiment. This situation underscores the inherent volatility and significant risks associated with the biotech sector, particularly in the nascent gene-editing space.

Intellia's lead candidate, nexiguran ziclumeran (nex-z), has seen its clinical trials paused following a patient death attributed to liver damage, despite targeting areas of high unmet medical need and benefiting from a partnership with Regeneron. While Intellia maintains a cash position of $670 million, projected to sustain operations until mid-2027, the ongoing regulatory uncertainty and elevated clinical risk profile render its stock highly speculative.

Sarepta's key Duchenne muscular dystrophy gene therapy, Elevidys, has been associated with two patient deaths from acute liver failure, with a third death occurring in another investigational therapy. This directly impacted the company's Q3 financial performance, with total revenue declining 15% year-over-year to $399.4 million and resulting in a non-GAAP net loss of $0.13 per share. Anticipated regulatory restrictions, including potential label changes and box warnings, are expected to further constrain Elevidys's commercial potential.

Key Decisions for Investors

• Investors should avoid new positions in Intellia Therapeutics (NTLA) and Sarepta Therapeutics (SRPT) due to severe clinical setbacks, patient deaths linked to liver damage, and significant regulatory uncertainty.
• Existing holders of SRPT and NTLA should re-evaluate their positions given the high risk of further clinical and regulatory hurdles, which could severely impact future commercial viability and stock performance.
• Closely monitor regulatory decisions regarding label changes, box warnings, or trial holds for both companies, as these will be critical indicators of future sales potential and risk profiles.
• Assess the broader implications for the gene-editing sector, as recurring liver toxicity issues may signal systemic risks that could affect other companies in this therapeutic area.